HC Wainwright Issues Negative Forecast for CervoMed Earnings

CervoMed Inc. (NASDAQ:CRVO) – Stock analysts at HC Wainwright cut their FY2025 earnings per share estimates for CervoMed in a research report issued to clients and investors on Monday, November 10th. HC Wainwright analyst R. Selvaraju now anticipates that the company will post earnings per share of ($2.84) for the year, down from their previous estimate of ($2.60). HC Wainwright currently has a “Buy” rating and a $25.00 price target on the stock. The consensus estimate for CervoMed’s current full-year earnings is ($1.88) per share. HC Wainwright also issued estimates for CervoMed’s Q4 2025 earnings at ($0.74) EPS, Q1 2026 earnings at ($0.86) EPS, Q2 2026 earnings at ($0.73) EPS, Q3 2026 earnings at ($0.64) EPS and FY2026 earnings at ($2.89) EPS.

CervoMed (NASDAQ:CRVO) last posted its quarterly earnings results on Friday, November 7th. The company reported ($0.84) EPS for the quarter, missing analysts’ consensus estimates of ($0.68) by ($0.16). CervoMed had a negative return on equity of 59.15% and a negative net margin of 290.72%.The business had revenue of $0.32 million during the quarter, compared to analysts’ expectations of $1.43 million.

Other equities analysts have also recently issued reports about the stock. Canaccord Genuity Group raised their target price on shares of CervoMed from $21.00 to $27.00 and gave the company a “buy” rating in a research note on Tuesday, July 29th. Zacks Research cut CervoMed from a “hold” rating to a “strong sell” rating in a report on Monday, October 13th. Chardan Capital reiterated a “buy” rating and issued a $15.00 target price on shares of CervoMed in a research report on Monday, August 11th. Roth Capital set a $20.00 price target on CervoMed and gave the company a “buy” rating in a report on Friday, October 17th. Finally, D. Boral Capital reaffirmed a “buy” rating and set a $31.00 price objective on shares of CervoMed in a report on Tuesday. One equities research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and three have assigned a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $21.86.

CervoMed Price Performance

CervoMed stock opened at $6.97 on Wednesday. CervoMed has a 1 year low of $1.80 and a 1 year high of $16.94. The firm’s 50 day moving average price is $8.06 and its 200-day moving average price is $8.18. The stock has a market cap of $64.49 million, a P/E ratio of -2.67 and a beta of -0.89.

Institutional Investors Weigh In On CervoMed

Several institutional investors have recently made changes to their positions in the company. Rhumbline Advisers raised its position in CervoMed by 35.5% in the 1st quarter. Rhumbline Advisers now owns 5,830 shares of the company’s stock worth $53,000 after purchasing an additional 1,526 shares during the period. GSA Capital Partners LLP bought a new stake in shares of CervoMed during the 3rd quarter worth approximately $91,000. HighTower Advisors LLC purchased a new position in CervoMed during the 1st quarter valued at $104,000. Marshall Wace LLP bought a new position in CervoMed in the 2nd quarter valued at $76,000. Finally, Bank of New York Mellon Corp purchased a new stake in CervoMed in the first quarter worth $110,000. Institutional investors own 25.15% of the company’s stock.

CervoMed Company Profile

CervoMed Inc, a biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. Its lead drug candidate is neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, frontotemporal dementia, and ischemic stroke recovery.